RSM 容诚 非经营性资金占用及其他关联资金 往来情况专项说明 安徽山河药用辅料股份有限公司 容诚专字|2025|230Z0307 号 容诚会计师事务所(特殊普通合伙) 中国 · 北京 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（bttp://ac.mof.gov.cn） 进行查测 录 | 序号 | 容 | 页码 | | --- | --- | --- | | | 非经营性资金占用及其他关联资金往来情况专项说明 | 1-2 | 2 非经营性资金占用及其他关联资金往来情况汇总表 3 安徽山河药用辅料股份有限公司全体股东: 我们接受委托,依据中国注册会计师审计准则审计了安徽山河药用辅料股份 有限公司〈以下简称"山河药辅"）2024年12月31日的合并及母公司资产负债 表，2024 年度的合并及母公司利润表、合并及母公司现金流量表和合并及母公司 所有者权益变动表以及财务报表附注,并于 2025年 4 月 21 日出具了容诚审字 [2025]230Z0469 号的无保留意见审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号 -- 上市公司资金 往来、对外担保的监管要求》的要求及深圳证券交 ...

RSM | 容诚 内部控制审计报告 容诚审字[2025]230Z0468 号 安徽山河药用辅料股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了安徽山河药用辅料股份有限公司（以下简称"山河药辅"）2024年 12 月 31 日的财务报告内部控制的有效性。 安徽山河药用辅料股份有限公司 容诚审字[2025]230Z0468 号 容诚会计师事务所(特殊普通合伙) 中国 · 北京 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查处 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mgf.gov.cn）"进行查处 " 内部控制审计报告 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是山河 药辅董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控 ...

国元证券股份有限公司 公司遵循全面性、重要性、客观性的评价原则，在确保评价工作独立、客观、 公正的基础上，围绕内部环境、风险评估、控制活动、信息与沟通、内部监督五 要素，对公司内部控制的设计及运行的效率、效果进行独立评价，内部涵盖了日 常生产经营管理的主要范围。 纳入评价范围的主要业务包括：治理结构、组织架构、内部审计、人力资源、 企业文化、销售及收款、采购及付款、生产管理、对外担保、研究与开发等；重 点关注的高风险领域主要包括资产管理、货币资金管理、投资管理、关联交易等。 上述纳入评价范围的单位、业务和事项以及高风险领域涵盖了公司经营管理 的主要方面，不存在重大遗漏。 二、内部控制的整体执行情况 （一）内部环境 1、治理结构 关于安徽山河药用辅料股份有限公司 2024 年度内部控制评价报告的核查意见 国元证券股份有限公司（以下简称"国元证券"或"保荐人"）作为安徽山 河药用辅料股份有限公司（以下简称"山河药辅"或"公司"）向不特定对象发 行可转换公司债券的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运 ...

安徽山河药用辅料股份有限公司 独立董事 2024 年度述职报告 周建平先生：现任公司独立董事。1978-1982 年获中国药科大学（原南京药 学院）药学学士学位，1982~1985 年在中国兽药监察所工作，1985~88 年获中国 药科大学药剂学硕士学位后留校，从事药剂学科研、教学工作至今。其中 1991~1992 年在日本近畿大学药学部访问学者；2001 年获中国药科大学药剂学博 士学位。现任中国药科大学药剂系教授（二级）、博士生导师；国家药典委员会 执行委员（药剂专业主任委员），江苏省药学会和南京药学会药剂专业主任委员、 常务理事；苏州韬略生物科技股份有限公司、江苏德源药业股份有限公司、江苏 万高药业股份有限公司独立董事。 作为独立董事，本人未在公司担任除独立董事以外的其他任何职务，没有为 公司提供财务、法律、管理咨询、技术咨询等服务，其配偶、父母、子女、主要 社会关系也未在公司任职，也未在公司主要股东公司担任任何职务，没有从公司 及其主要股东或有利害关系的机构和人员取得额外的未予披露的其他利益，不存 在影响独立性的情况。 二、独立董事年度履职情况 （一）出席董事会及专门委员会和股东大会的情况 本人本着勤 ...

安徽山河药用辅料股份有限公司 独立董事 2024 年度述职报告 述职人：王宏 （一）出席董事会及专门委员会和股东大会的情况 本人本着勤勉尽责的态度，参加公司召开的董事会并列席公司股东大会。 自任职日 2024 年 8 月 1 日至 2024 年 12 月 31 日，公司共召开董事会 3 次，本人亲自出席董事会会议 3 次，没有连续两次未亲自出席会议的情况。在 一、独立董事基本情况 王宏女士：现任公司独立董事。本科学历，中国注册会计师、中国注册资产 评估师、注册土地估价师。历任安徽省国防工业办公室皖东机械厂财务科会计， 安徽中华会计师事务所执业助理，安徽省资产评估事务所部门经理，安徽皖资会 计师事务所所长，曾赴美国参加注册会计师行业交流、培训。现任芜湖长信科技 股份有限公司（股票代码 300088）独立董事。 作为独立董事，本人未在公司担任除独立董事以外的其他任何职务，没有为 公司提供财务、法律、管理咨询、技术咨询等服务，其配偶、父母、子女、主要 社会关系也未在公司任职，也未在公司主要股东公司担任任何职务，没有从公司 及其主要股东或有利害关系的机构和人员取得额外的未予披露的其他利益，不存 在影响独立性的情况。 ...

安徽山河药用辅料股份有限公司 董事会 二〇二五年四月二十二日 关于独立董事 2024 年度保持独立性情况的专项意见 安徽山河药用辅料股份有限公司（以下简称"公司"）董事会根 据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等要求，并结合独立 董事出具的《2024 年度独立董事关于独立性自查情况的报告》，就公 司在任独立董事的独立性情况进行评估并出具如下专项意见： 公司在任独立董事王宏女士、林平先生及周建平先生均能够胜任 独立董事的职责要求，其未在公司担任除独立董事及董事会专门委员 会委员以外的任何职务，其直系亲属均未在公司及其下属企业任职； 独立董事及其直系亲属也未在公司主要股东公司担任任何职务，与公 司以及主要股东之间不存在妨碍其进行独立客观判断的关系，不存在 影响独立董事独立性的情况，符合《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等法律、法规、规范性文件及《公司章程》中关于独立董事 的任职资格及独立性的相关要求。 安徽山河药用辅料股份有限公司 ...

安徽山河药用辅料股份有限公司 独立董事 2024 年度述职报告 述职人：顾光（已离职） 本人顾光在 2024 年度担任安徽山河药用辅料股份有限公司（以下简称"公 司"）的独立董事，根据《公司法》、《证券法》、《上市公司独立董事管理办 法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》及《公司章程》的规定和要求，忠实履行了独立董事的职责，谨慎、认真、 勤勉地行使了独立董事的权利，积极出席相关会议，认真审议董事会各项议案， 对公司相关事项发表同意意见。因公司第五届董事会任期届满，本人自 2024 年 8 月起不再担任公司独立董事、审计委员会主任委员、薪酬与考核委员会委员， 现就本人 2024 年度履职情况汇报如下： 一、独立董事基本情况 顾光女士：管理学硕士，中国注册会计师(非执业会员)。历任安徽大学财务 管理系主任、会计学系主任、会计专硕中心主任。安徽大学商学院副教授、硕士 生导师，现已退休。现任芜湖埃泰克汽车电子股份有限公司、阳光电源股份有限 公司独立董事。 作为独立董事，本人未在公司担任除独立董事以外的其他任何职务，没有为 公司提供财务、法律、管理咨询、技术咨询等服务，其配偶 ...

安徽山河药用辅料股份有限公司 独立董事 2024 度述职报告 述职人：林平 本人林平在 2024 度担任安徽山河药用辅料股份有限公司（以下简称"公司"） 的独立董事，根据《公司法》、《证券法》、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《公司章程》的规定和要求，在 2024 年度工作中忠实履行独立董事的职责， 积极出席相关会议，认真审议董事会各项议案，对公司重大事项发表了独立意见， 切实维护了公司的整体利益和全体股东特别是中小股东的合法权益。现将 2024 度履行职责情况述职如下： 一、独立董事基本情况 林平先生：现任公司独立董事。本科学历，三级律师，民革党员；1992 年 在安徽省第三经济律师事务所从事专职律师工作；1998 年起执业于安徽协力律 师事务所；2002 年担任安徽协利律师事务所主任；曾任第九届安徽省律师协会 常务理事、第一届合肥仲裁委员会仲裁员、合肥市庐阳区人民法院执法执纪监督 员、民革安徽省社会与法制委员会委员；现任最高人民检察院民事行政专家库成 员、亳州仲裁委仲裁员、安徽六国化工股份有限公司、皖创环保股份有限公司、 合肥医 ...

Financial Performance - The company's revenue for Q1 2025 was ¥247,871,756.30, representing a 4.28% increase compared to ¥237,688,540.94 in the same period last year[4] - Net profit attributable to shareholders decreased by 5.30% to ¥47,176,895.69 from ¥49,815,076.00 year-on-year[4] - The company's basic earnings per share decreased by 4.76% to ¥0.20 from ¥0.21 in the same period last year[4] - Net profit for the current period was ¥46,658,366.21, a decrease of 7.4% from ¥50,518,085.80 in the previous period[22] - Earnings per share (EPS) for the current period was ¥0.20, down from ¥0.21 in the previous period[23] Cash Flow - The net cash flow from operating activities improved by 37.36%, reaching -¥6,407,841.51 compared to -¥10,229,557.31 in the previous year[4] - Operating cash inflow totaled $191,178,322.84, an increase of 6.8% from $179,860,893.79 in the previous period[24] - Net cash outflow from operating activities was -$6,407,841.51, improving from -$10,229,557.31 in the prior period[24] - Investment cash inflow reached $207,987,163.69, up from $123,826,360.05, marking a significant increase of 68%[25] - Net cash flow from investment activities was $30,076,395.09, a turnaround from -$4,082,863.19 in the previous period[25] - Cash inflow from financing activities amounted to $13,010,000.00, compared to $8,222,600.00 in the last period, reflecting a growth of 58.5%[25] - Net cash flow from financing activities improved to $3,750,295.69 from -$23,377,116.80 in the previous period[25] - The ending cash and cash equivalents balance was $196,985,492.35, up from $112,793,039.47, indicating a strong liquidity position[25] - Cash received from the recovery of investments was $205,000,000.00, significantly higher than $120,000,471.85 in the previous period[24] - Total cash outflow from investment activities was $177,910,768.60, compared to $127,909,223.24 previously, reflecting increased investment efforts[25] Assets and Liabilities - The total assets at the end of the reporting period increased by 1.97% to ¥1,590,491,570.21 from ¥1,559,730,388.14 at the end of the previous year[4] - Total liabilities decreased to ¥568,174,417.08 from ¥584,430,625.34, a reduction of 2.8%[20] - The company's total equity attributable to shareholders rose by 5.25% to ¥952,505,623.84 from ¥905,009,796.36 at the end of the previous year[4] - The company's total equity rose to ¥1,022,317,153.13, compared to ¥975,299,762.80, marking an increase of 4.8%[20] Investments and Income - The company reported a 30.95% decrease in investment income to ¥2,586,300.00 compared to the previous year[9] - Investment income decreased to ¥2,586,319.40 from ¥3,745,773.20, a decline of 30.9%[22] - The company reported a fair value change loss of ¥526,013.84, contrasting with a gain of ¥2,670,735.94 in the previous period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,829[12] - The largest shareholder, Yin Zhenglong, holds 26.90% of the shares, totaling 63,057,454 shares[12] - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. is the second-largest shareholder with a 10.16% stake, amounting to 23,819,959 shares[12] - The company has a total of 47,293,090 shares under lock-up due to executive restrictions[15] - The company repurchased 1,825,500 shares by the end of Q3 2024[13] - There are no changes in the top 10 shareholders participating in margin financing and securities lending[13] Inventory and Receivables - Accounts receivable increased by 49.36% to ¥158,714,100.00, primarily due to increased sales[8] - Accounts receivable increased to 158,714,089.03 RMB from 106,265,735.78 RMB, reflecting a growth of approximately 49.3%[18] - Inventory decreased to 81,234,134.67 RMB from 88,758,572.74 RMB, indicating a decline of about 8.6%[18] - The total current assets at the end of the period are 1,055,154,894.31 RMB, compared to 1,021,531,868.21 RMB at the beginning of the period, showing an increase of approximately 3.3%[18] Operating Costs - Total operating costs amounted to ¥200,329,332.30, up from ¥189,620,354.92, reflecting a rise of 5.9%[21] - Research and development expenses for the current period were ¥12,333,757.33, an increase of 4.7% from ¥11,783,747.62[21]

Financial Performance - The company's operating revenue for 2024 reached ¥882,573,320.58, representing a 5.16% increase compared to ¥839,259,534.36 in 2023[16]. - Net profit attributable to shareholders decreased by 26.07% to ¥119,424,741.26 in 2024 from ¥161,535,015.82 in 2023[16]. - The basic earnings per share fell by 26.09% to ¥0.51 in 2024, down from ¥0.69 in 2023[16]. - The total assets at the end of 2024 were ¥1,559,730,388.14, a 1.10% increase from ¥1,542,710,563.50 at the end of 2023[16]. - The company reported a net cash flow from operating activities of ¥118,332,669.23 in 2024, a decrease of 10.56% from ¥132,298,332.70 in 2023[16]. - The weighted average return on equity decreased to 13.67% in 2024 from 20.53% in 2023, a decline of 6.86%[16]. - The company has seen a decline in net profit after deducting non-recurring gains and losses, with a decrease of 26.45% to ¥101,157,550.11 in 2024 from ¥137,540,602.85 in 2023[16]. - The company reported a negative net profit in the fourth quarter of 2024, amounting to -¥3,001,117.77, indicating challenges in maintaining profitability[18]. Dividend Policy - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares (including tax) to all shareholders based on the total share capital as of the dividend record date, excluding 1.8255 million shares in the repurchase account[4]. - The company has not issued any bonus shares during the profit distribution plan, indicating a focus on cash dividends instead[4]. - The 2023 profit distribution plan was approved, with a cash dividend of 2.5 RMB per 10 shares, totaling 58.1537 million RMB distributed[147]. - For the 2024 profit distribution plan, a cash dividend of 3.0 RMB per 10 shares is proposed, with a total cash dividend amounting to approximately 69.79 million RMB[150]. Industry Position and Market Trends - The company is positioned in the pharmaceutical manufacturing industry, focusing on the pharmaceutical excipients sector, which is experiencing significant transformation and development[25]. - The government has increased support for the biopharmaceutical industry, emphasizing the development of innovative drugs and medical devices, which is expected to enhance market opportunities[26]. - The domestic pharmaceutical manufacturing industry achieved a revenue of CNY 25,298.5 billion in 2024, remaining flat year-on-year, which is below the overall industrial growth rate of +2.1%[27]. - The pharmaceutical manufacturing industry saw a profit of CNY 3,420.7 billion in 2024, representing a year-on-year decline of 1.1%[27]. - The market for pharmaceutical excipients is expected to grow significantly, driven by policies encouraging the development of high-end excipients and new adjuvants for vaccines[27]. Product Development and Innovation - The company has developed 50 products that have obtained drug excipient registration numbers from the CDE, indicating a strong product pipeline[30]. - The company focuses on optimizing product quality and expanding its product line, with a commitment to innovation based on market demand[30]. - The company has accelerated the research and industrialization of new fields such as injectable excipients and premix excipients[36]. - The company aims to complete 3-4 new product CDE registrations and increase R&D investment to meet market demand and improve product performance[96]. Research and Development - The company has invested in a new pharmaceutical excipient production base to expand capacity and strengthen its leading position in the industry[43]. - The R&D budget has been increased by 25% to support the development of innovative technologies and products[130]. - The number of R&D personnel increased by 8.13% to 173 in 2024, compared to 160 in 2023[61]. - Research and development expenses for 2024 were ¥40,952,648.76, a decrease of 2.38% compared to ¥41,952,772.69 in 2023[60]. Corporate Governance - The company has a complete and effective internal control system that spans all levels and aspects of its operations, continuously improving governance standards[112]. - The board of directors consists of 7 members, including 3 independent directors, which exceeds one-third of the total number of directors, complying with legal and regulatory requirements[109]. - The company maintains complete independence in business, personnel, assets, institutions, and finance from its controlling shareholder, ensuring no reliance on or unfair transactions with the controlling shareholder[113]. - The company has established a transparent investor relations management system, ensuring timely and accurate information disclosure to all shareholders[111]. Environmental Responsibility - The company holds valid pollution discharge permits from the Huainan Ecological Environment Bureau, expiring on May 12, 2028, and May 28, 2028[158]. - The company reported a total hazardous waste discharge of 2.58 tons, with no exceedances of discharge standards[159]. - The company has implemented strict environmental protection measures in accordance with relevant regulations and standards[158]. - The company has invested over 6 million yuan in environmental protection facilities and operations during the reporting period[164]. Risk Management - The company has outlined potential risks in its future development outlook, urging investors to pay attention to these risks[4]. - The company faces risks from fluctuations in raw material prices, particularly for key ingredients like wood pulp and refined cotton, which could impact profit margins if costs cannot be passed on to customers[97]. - The company emphasizes quality control throughout the production process to mitigate risks associated with operational errors and raw material quality[99]. Market Strategy - The marketing strategy will focus on "innovation industry, create market," expanding overseas markets and enhancing product recognition and market influence[93]. - The company is actively pursuing opportunities in the health food and plant capsule markets, as well as innovations in traditional Chinese medicine[93]. - The company plans to enhance its market presence and enhance product offerings through new technology development and strategic acquisitions[122]. Employee Management - The total number of employees at the end of the reporting period is 1,065, with 855 from the parent company and 209 from major subsidiaries[143]. - Annual training plans are developed by each department based on needs assessment and past training feedback, approved by the human resources department[146]. - The company maintains a salary policy that aligns with job value and differentiates based on technical and professional capabilities[145]. Shareholder Engagement - The annual shareholders' meeting had a participation rate of 43.24% on May 16, 2024[117]. - The first interim shareholders' meeting in 2024 had a participation rate of 31.56% on August 1, 2024[117]. - The second interim shareholders' meeting in 2024 had a participation rate of 28.16% on August 19, 2024[118]. - The third interim shareholders' meeting in 2024 had a participation rate of 28.85% on November 8, 2024[118].